© Sander van der Wel/Flickr
FrieslandCampina DOMO’s new Human Milk Oligosaccharide (HMO) ingredient for use in infant formulas has been approved for use by the EU and received GRAS (generally recognised as safe) status from the US Food and Drug Administration.
2’-fucosyllactose (2’-FL) can now be used for infant formulas in both markets, and the company says this is an important step towards launching its first HMO product by the end of the year.
HMOs such as 2’-FL are naturally occurring ingredients found in breastmilk which help the development of infants, and recent clinical trials suggest that 2’-FL in particular plays a key role in protecting the health of newborn babies.
FrieslandCampina DOMO’s 2’-FL ingredient will be made commercially available through its Aequival brand, and will be the first product in a range of HMOs that will be available to consumers in the near future.
The ingredient was developed in partnership with US-based Glycosyn as part of a product development agreement signed by the two companies in 2016.
Additionally, a dedicated 2’-FL plant will be constructed in Italy later this year, allowing the company to begin large-scale production of the ingredient.
Aafke Keizer, managing director FrieslandCampina DOMO said: “Our 75 years of expertise in infant nutrition were essential in setting up a safe, smooth production process that ensures a continuously high-quality product such as 2’-FL.
“DOMO is the market leader in oligosaccharides and has an extensive portfolio of infant nutrition ingredients, to which 2’-FL is the perfect addition, helping our customers to develop the next generation of infant formula.”
Godert Zijlstra, business development director HMOs at FrieslandCampina added: “By the end of 2018, our first HMO, Aequival 2’-FL, will be commercially available.
“From our state-of-the-art new facilities, we will be formulating and launching a broad range of HMOs over the next years, in line with our mission to give infants a great start in life.
“After decades of experience in infant nutrition and oligosaccharides, we have embarked on a new and exciting time in the development of breakthrough innovations for our industry.”
© FoodBev Media Ltd 2018